skip to content
Primary navigation


Drug - Tudorza Pressair [Forest Labratories, Inc.]

June 2013

Therapeutic area - COPD

Approval criteria

  • Patient has a diagnosis of COPD AND
  • Patient is greater than 18 years of age AND
  • Patient has had an inadequate response or is intolerant to, Spiriva as documented in clinical progress notes

Quantity limit

1 inhaler per month

Background information

TUDORZA PRESSAIR is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top